Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
AssigneesCancer Research Campaign Tech. Ltd., Zeneca Limited
InventorsKenneth D. Bagshawe, Gordon T. Rogers, Surinder K. Sharma
Life of this patent
Estimating the term…
Abstract
A treatment for tumors to which antibody A5B7 binds is disclosed. A5B7 is a monoclonal antibody which binds to carcinoembryonic antigen. The treatment comprises administering to a host in need of such treatment an effective amount of a system which comprises: a conjugate comprising antibody A5B7 or a humanized version of A5B7 linked to an enzyme selected from the group consisting of carboxypeptidase G2 (CPG2), nitroreductase, a human enzyme, a non-human enzyme rendered non-immunogenic in man and a humanized catalytic antibody; and a prodrug convertible under the influence of the conjugate into a cytotoxic drug.
Claims24
A conjugate comprising A5B7 antibody and an enzyme selected from the group consisting of carboxypeptidase G2 enzyme and nitroreductase.
A conjugate comprising A5B7 antibody and a member of the group consisting of a human enzyme, a non-human enzyme rendered non-immunogenic in man and a humanized catalytic antibody.
A conjugate comprising A5B7 antibody and carboxypeptidase G2 enzyme.
Dependencies are inferred from the claim text.